Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael R. Migden"'
Autor:
Zhen Chen, Chrysalyne D. Schmults, Elizabeth Stankevich, Michael R. Migden, Israel Lowy, Nikhil I. Khushalani, Leonel Hernandez-Aya, Anne Lynn S. Chang, Danny Rischin, Annette M. Lim, Axel Hauschild, Siyu Li, Emmanuel Okoye, Matthew G. Fury, Alexander Guminski, Karl D. Lewis, Brett G.M. Hughes, Jocelyn Booth, Dirk Schadendorf
Publikováno v:
Journal of Clinical Oncology. 38:10018-10018
10018 Background: Cemiplimab monotherapy achieves clinically meaningful activity in pts with advanced CSCC (metastatic [mCSCC] or locally advanced [laCSCC] not amenable to curative surgery or curative radiation) and has a safety profile consistent wi
Autor:
Vera Mastey, Chieh-I Chen, Anne Lynn S. Chang, Sherrif F. Ibrahim, Medha Sasane, Anna C. Pavlick, Alexander Guminski, Michael R. Migden, Israel Lowy, Denise Bury, Axel Hauschild, Matthew G. Fury, Guilherme Rabinowits, Siyu Li, Danny Rischin, Chrysalyne D. Schmults, Zhen Chen
Publikováno v:
Journal of Clinical Oncology. 38:10033-10033
10033 Background: Cemiplimab-rwlc (cemiplimab), a PD-1 Inhibitor, showed a robust clinical response in patients (pts) with metastatic (mCSCC) or locally advanced (laCSCC) CSCC not eligible for curative surgery/radiation. This post hoc exploratory ana
Autor:
Karl D. Lewis, Carola Berking, Chrysalyne D. Schmults, Jocelyn Booth, Leonel Hernandez-Aya, Israel Lowy, Anne Lynn S. Chang, Danny Rischin, Nikhil I. Khushalani, Dirk Schadendorf, Elizabeth Stankevich, Alexander Guminski, Michael R. Migden, Gregory A. Daniels, Matthew G. Fury, Axel Hauschild, Siyu Li, Deborah J.L. Wong, Vladimir Jankovic, Friedegund Meier
Publikováno v:
Journal of Clinical Oncology. 37:6015-6015
6015 Background: Cemiplimab (REGN2810) produced substantial antitumor activity with durable responses in Phase 1 CSCC expansion cohorts and Phase 2 metastatic (m) CSCC cohort. We now present the primary analysis of the Phase 2 laCSCC cohort (NCT02760
Autor:
Badri Modi, Anne Lynn S. Chang, Axel Hauschild, Nikhil I. Khushalani, Elizabeth Stankevich, Murad Alam, Siyu Li, Annette M. Lim, Brett G.M. Hughes, Lara Dunn, Michael R. Migden, Vladimir Jankovic, Leonel Hernandez-Aya, Jocelyn Booth, Chrysalyne D. Schmults, Matthew G. Fury, Danny Rischin, Ralf Gutzmer, Israel Lowy, Alexander Guminski
Publikováno v:
Journal of Clinical Oncology. 37:9526-9526
9526 Background: Primary analysis (Oct 2017) of cemiplimab (REGN2810) in pts with mCSCC in a Phase 2 study demonstrated substantial antitumor activity, durable responses, and acceptable safety profile. We now report 12-month follow-up data from these